Contents

Current Drug Targets, Volume 9 - Number 1

Editorial [Hot Topic: Diabetic Neuropathy (Guest Editor: Eva L. Feldman)]

, 9(1): 1 - 2

Eva L. Feldman


DOI: 10.2174/138945008783431709




Criteria for Creating and Assessing Mouse Models of Diabetic Neuropathy

, 9(1): 3 - 13

Eva L. Feldman, Kelli A. Sullivan, Stephen I. Lentz and John L. Roberts Jr.


DOI: 10.2174/138945008783431763




Aldose Reductase, Still a Compelling Target for Diabetic Neuropathy

, 9(1): 14 - 36

Peter J. Oates


DOI: 10.2174/138945008783431781




Is C-Peptide Replacement the Missing Link for Successful Treatment of Neurological Complications in Type 1 Diabetes?

, 9(1): 37 - 46

Anders A.F. Sima and Hideki Kamiya


DOI: 10.2174/138945008783431745




Growth Factors as Therapeutics for Diabetic Neuropathy

, 9(1): 47 - 59

Nigel A. Calcutt, Corinne G. Jolivalt and Paul Fernyhough


DOI: 10.2174/138945008783431727




Pro-Inflammatory Mechanisms in Diabetic Neuropathy: Focus on the Nuclear Factor Kappa B Pathway

, 9(1): 60 - 67

Norman E. Cameron and Mary A. Cotter


DOI: 10.2174/138945008783431718




Cyclooxygenase-2 Pathway as a Potential Therapeutic Target in Diabetic Peripheral Neuropathy

, 9(1): 68 - 76

Rodica Pop-Busui, Aaron P. Kellogg and Hsinlin Thomas Cheng


DOI: 10.2174/138945008783431691




The Potential Role of Angiotensin Converting Enzyme and Vasopeptidase Inhibitors in the Treatment of Diabetic Neuropathy

, 9(1): 77 - 84

Mark A. Yorek


DOI: 10.2174/138945008783431736




Metabotropic Glutamate Receptors (mGluRs) and Diabetic Neuropathy

, 9(1): 85 - 93

James W. Russell, Muragundla Anjaneyulu and Alison Berent-Spillson


DOI: 10.2174/138945008783431772




The Antioxidant Response as a Drug Target in Diabetic Neuropathy

, 9(1): 94 - 100

Andrea M. Vincent, James L. Edwards, Mahdieh Sadidi and Eva L. Feldman


DOI: 10.2174/138945008783431754




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science